{"id":"W7116917451","doi":"10.1016/j.annonc.2025.10.716","title":"1005P MET testing and treatment (tx) sequencing after progression of disease (PD) on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Final analysis of a global real-world (rw) study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Disease; C-Met; MEDLINE; Respiratory disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00125165,0.0006174757,0.0005030475,0.0004508166,0.0002086032,0.0007218451,0.0005451204,0.0005335105,0.001060901],"category_scores_gemma":[0.001411186,0.0003901978,0.0008717709,0.000810275,0.000446947,0.0006382463,0.0006659057,0.0007219125,0.000325978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003955375,"about_ca_system_score_gemma":0.0003433249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001624559,"about_ca_topic_score_gemma":0.003718535,"domain_scores_codex":[0.9992968,0.0002828551,0.00004219095,0.0002130349,0.00008320407,0.0000820194],"domain_scores_gemma":[0.998845,0.0002266959,0.0004408562,0.0001793528,0.000105991,0.0002021643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.014649,0.0003204238,0.9655699,0.0001096723,0.001527961,0.000193512,0.0001340327,0.0008198901,0.002900905,0.00007793975,0.0008553576,0.01284158],"study_design_scores_gemma":[0.001096798,0.002744176,0.9918768,0.00002186589,0.0008164555,0.0005011903,0.0001407328,0.0006811336,0.0006620559,0.00008010652,0.001360808,0.00001780754],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974678,0.0002185399,0.0001559602,0.00003287878,0.000005662129,0.00002656553,0.00172746,0.000008548305,0.0003566299],"genre_scores_gemma":[0.9938262,0.0001359638,0.0003172546,0.00007558726,0.00001212816,0.00003851191,0.005299971,0.00001145272,0.0002829938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001624559,"threshold_uncertainty_score":0.006619453,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07739625107389356,"score_gpt":0.4460854616136848,"score_spread":0.3686892105397913,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}